<p>You are about to enter the B. Braun Melsungen AG (global) website. If you are from United States, visit the U. S. Website</p>

United States - B. Braun Medical Inc.

Australia - B. Braun Australia Pty. Ltd

<p>Not all products are registered and approved for sale in all countries or regions. Indications of use may also vary by country and region. Please contact your country representative for product availability and information. Product images are for reference only.</p>

Cancel

You have successfully logged out.

PEPCAD Japan SVD

SeQuent® Please vs. POBA (SeQuent® NEO) in small vessel de novo lesions

A multicenter randomized comparison of paclitaxel-coated balloon with plain balloon angioplasty in patients with small vessel disease

_{Funatsu A et al. Clin. Res. Cardiol. 2017; 106(10): 824-32}

Medical Professional

This information is meant for medical professionals only. Please confirm that you are a medical professional before accessing the information.

Confirm Yes, I am a health care professional. Cancel No, I am not a health care professional.

Key findings

TVF was low for treatment of SVD with DCB. In addition, LLL was observed significantly more frequent in the DCB group in comparison to the POBA group.

Description

Design: Randomized | Open-label | Prospective | Multicenter | Superiority (test for difference)

Indication: De novoMain patient inclusion criterion: Reference vessel diameter ≤ 2.75 mm, ≥ 2 mm

Primary endpoint: TVF @ 6-month follow-up. Components of TVF:

Cardiac death: Death due to target vessel
MI: Creatine phosphokinase (CPK) elevation C3 times the normal value in addition to continuous chest symptoms and electrocardiogram changes due to target vessel
Composite events: Revascularization of target vessel (PCI or CABG)

Secondary endpoints:

TLR @ 6-month follow-up: Ischemia-driven if the lesion revealed restenosis (DS ≥ 50) associated with symptom or presence of ischemia, or if lesion diameter stenosis > 70% (by core laboratory QCA), even in the absence of clinical or functional ischemia
LLL @ 6-month follow-up

DAPT: 6 months

Results

Patients: In total, 135 patients were enrolled and randomized into a DCB group and POBA group with a ratio of 2:1. Some patients were excluded from the trial due to unsuccessful treatment, consent withdrawal and protocol violation. Follow-up was performed in 88 patients from the DCB group and in 39 patients from the POBA group.

Baseline characteristics: The two treatment groups were well balanced. Apart from a higher proportion of diabetes mellitus in the DCB group, there were no statistically significant differences between the two treatment groups.

Primary endpoints: TVF was low in the DCB group

	DCB n = 88	POBA n = 39	p-value
TVF	3.4 %	10.3 %	0.20
Cardiac death	0 %	0 %	-
MI	0 %	0 %	-
TLR	2.3 %	10.3 %	0.07

Secondary endpoints:

	DCB	POBA	p-value
Clinical follow-up
No. of patients	88	39	-
TLR	2.3 %	10.3 %	0.07
Angiographic follow-up
No. of lesions	103	43	-
LLL	0.01 ± 0.31 mm	0.32 ± 0.34 mm	< 0.01

Further information on PubMed

Get in touch with our Coronary Drug Coated Balloon experts

Coronary Drug Coated Balloon contact form

Stay connected with My B. Braun

With your personalized account, your online experience will be easier, more comfortable and safe.

person_outline My B. Braun